Evidence map›Paper›PMID 42624967›Full record

ArticleBone marrow transplantation2026

Long-term complications after total body irradiation in children younger than 4 years transplanted for acute lymphoblastic leukemia.

Quentin Neven, Julie Berbis, Gérard Michel, Carine Domenech, Cécile Pochon, Sandrine Visentin, Cécile Renard, André Baruchel, Mony Fahd, Virginie Gandemer and 16 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Quentin NevenHematology and immunology department, Robert Debré hospital, GHU APHP Nord, Université Paris Cité, Paris, France.
Julie BerbisDepartment of Public Health, Aix Marseille Univ, APHM, CERESS, Marseille, France.
Gérard MichelDepartment of pediatric hematology, immunology and oncology, Aix Marseille Univ, APHM, CERESS, La Timone Children's Hospital, Marseille, France.ORCID http://orcid.org/0000-0002-0018-5709
Carine DomenechDepartment of Pediatric Hematology and Oncology, IHOP, Hospices Civils de Lyon, Lyon 1 University, Lyon, France.ORCID http://orcid.org/0000-0002-9349-4139
Cécile PochonDepartment of Pediatric Onco-Hematology, Hôpital d'Enfants de Brabois, Vandoeuvre Les Nancy, France.
Sandrine VisentinDepartment of Pediatric Hematology, Immunology and Oncology, La Timone Children's Hospital, Marseille, France.
Cécile RenardDepartment of Pediatric Hematology and Oncology, IHOP, Hospices Civils de Lyon, Lyon, France.
André BaruchelHematology and immunology department, Robert Debré hospital, GHU APHP Nord, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0003-0120-6089
Mony FahdHematology and immunology department, Robert Debré hospital, GHU APHP Nord, Université Paris Cité, Paris, France.
Virginie GandemerDepartment of Pediatric Hematology and Oncology, University Hospital of Rennes, Rennes, France.
Marilyne PoiréePediatric Hematology and Oncology Department, University Hospital L'Archet, Nice, France.
Charlotte JubertDepartment of Pediatric Hematology and Oncology, University Hospital of Bordeaux, Bordeaux, France.
Stéphane DucassouDepartment of Pediatric Hematology and Oncology, University Hospital of Bordeaux, Bordeaux, France.
Catherine PaillardDepartment of Pediatric Hematology-oncology, University Hospital, Strasbourg, France.
Laura Olivier-GougenheimDepartment of Pediatric Hematology and Oncology, University Hospital of Toulouse, Toulouse, France.
Alexandre TheronDepartment of Pediatric Hematology and Oncology, University Hospital, Montpellier, France.ORCID http://orcid.org/0000-0001-8793-4903
Corinne Armari-AllaDepartment of Pediatric Hematology-Oncology, University Hospital of Grenoble, Grenoble, France.
Justyna KanoldDepartment of Pediatric Hematology and Oncology, CIC Inserm 501, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
Sandrine Thouvenin-DouletDepartment of Pediatric Hematology-Oncology, University Hospital St Etienne, St Etienne, France.
Mathilde Veneziano BrocciaDepartment of Pediatric Hematology, Immunology and Oncology, Aix Marseille Univ, APHM, INSERM, INRAE, C2VN, La Timone Children's Hospital, Marseille, France.
Caroline ThomasDepartment of Pediatric Hematology and Oncology, CHU de Nantes, Nantes, France.
Marie-Dominique TaboneDepartment of Pediatric Hematology, Immunology and Oncology, Armand Trousseau Hospital, Sorbonne University, APHP, Paris, France.ORCID http://orcid.org/0000-0002-9486-8454
Guy LevergerSorbonne University, INSERM, CRSA, UMR_S938, APHP, Groupe Hospitalier Sorbonne Université, Armand Trousseau Hospital, Paris, France.
Pascal AuquierDepartment of Public Health, Aix Marseille Univ, APHM, CERESS, Marseille, France.ORCID http://orcid.org/0000-0003-3496-1996
Jean-Hugues DalleHematology and immunology department, Robert Debré hospital, GHU APHP Nord, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0002-8406-0793
Paul SaultierDepartment of Pediatric Hematology, Immunology and Oncology, Aix Marseille Univ, APHM, INSERM, INRAE, C2VN, La Timone Children's Hospital, Marseille, France. paul.saultier@ap-hm.fr.ORCID http://orcid.org/0000-0002-6327-0898

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Total body irradiation (TBI)-based conditioning is the standard regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in high-risk or relapsed pediatric acute lymphoblastic leukemia (ALL), but is variably used before age 4 because of concerns about long-term toxicity. Long-term physical, educational, and quality-of-life outcomes were assessed in patients from the French long-term follow-up program LEA who underwent TBI-based HSCT for ALL at 2 to <4 years of age (younger group, n = 37) and compared with those of matched prepubertal older children transplanted at ≥4 years (older group, n = 105). After a mean follow-up of 15.6 years, the number of complications was similar in the two groups (3.3 vs 3.2, p = 0.90). Among the 20 complications analyzed, pulmonary dysfunction was the only event that differed significantly, being more frequent in the older group (43% vs 19%, p = 0.01). In a multivariate multistate model, age group was not associated with a higher risk of transition to a greater complication burden (HR 1.05, 95% CI 0.83-1.32; p = 0.70). Educational outcomes and quality of life were also comparable. These findings do not suggest greater long-term toxicity in children undergoing TBI-based HSCT at 2 to <4 years of age and support reconsideration of the lower age limit for its use.

Identifiers

PMID42624967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.